Rosenbach, Kevin
Park, Michelle
Sanchirico, Marie http://orcid.org/0000-0001-9985-5583
Nwose, Oliseyenum
Paris, Kenneth
Funding for this research was provided by:
Shire Human Genetic Therapies Inc
Takeda Pharmaceuticals USA, Inc
Article History
Received: 27 May 2022
Accepted: 19 January 2023
First Online: 21 February 2023
Declarations
:
: Not applicable.
: All patients and their parents or caregivers were informed of the study’s purpose and provided written informed consent.
: The authors affirm that the manuscript contains no individual person’s data in any form.
: KR has been a participant in advisory boards/consulting, speakers’ bureaus, and an investigator on clinical trials and others for Shire/Takeda; an advisory board participant and speakers’ bureau participant for neuromuscular immune disease indications for CSL; a speaker for the Immune Deficiency Foundation and the Ig National Society; on advisory boards for pharmacy benefit managers representing immunology specialists and patients with PIDD; a consultant for RMS/Koru Medical Systems; an advisory board participant for Octapharma, Therapure Evolve, and Catalyst Pharmaceutical companies; and a consultant for KabaFusion Specialty Pharmacy. MP is an employee of Takeda Development Center Americas, Inc. and is eligible for Takeda stock. MS is an employee of Takeda Pharmaceuticals USA, Inc. and eligible for Takeda stock. ON is an employee of Takeda Pharmaceuticals USA, Inc., and a Takeda shareholder. KP has been a participant in advisory boards/consulting, a speaker on the use of IG and shared decision-making, an investigator on clinical trials and others for Shire/Takeda, and a speaker for the Immune Deficiency Foundation.